TY - JOUR
T1 - Music rhythm perception and production relate to treatment response in schizophrenia
AU - Honda, Shiori
AU - Matsushita, Karin
AU - Noda, Yoshihiro
AU - Tarumi, Ryosuke
AU - Nomiyama, Natsumi
AU - Tsugawa, Sakiko
AU - Nakajima, Shinichiro
AU - Mimura, Masaru
AU - Fujii, Shinya
N1 - Funding Information:
This work was funded by Japan Society for the Promotion of Science (JSPS) ( 21J2006 , 16H06253 , 18H02755 , 22H03002 , 16K16483 , and 16K09024 ), Japan Research Foundation for Clinical Pharmacology , Naito Foundation , Uehara Memorial Foundation , Takeda Science Foundation , Daiichi Sankyo Research Program , and Novartis Research Program .
Funding Information:
S.F. has received a Grant-in-Aid for Young Scientists B and a Grant-in-Aid for Scientific Research B from JSPS and research grants from JST COI-NEXT and Keio University Academic Development Funds . S.F. has also received research support from no new folk studio Inc. and Odakyu Railway within the past three years.
Funding Information:
Y.N. has received a Grant-in-Aid for Young Scientists and Grant-in-Aid for Scientific Research (B) from JSPS, research grants from Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from TEIJIN PHARMA LIMITED and Inter Reha Co., Ltd . Y.N. also receives research grants from Japan Health Foundation , Meiji Yasuda Mental Health Foundation , Mitsui Life Social Welfare Foundation , Takeda Science Foundation , SENSHIN Medical Research Foundation , Health Science Center Foundation , Mochida Memorial Foundation for Medical and Pharmaceutical Research , Taiju Life Social Welfare Foundation , and Daiichi Sankyo Scholarship Donation Program . Y.N. has received speaker's honoraria from Dainippon Sumitomo Pharma, MOCHIDA PHARMACEUTICAL CO., LTD., and Yoshitomiyakuhin Corporation within the past three years. Y.N. also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., BrainBox Ltd., and Miyuki Giken Co., Ltd.
Funding Information:
S.N. has received a Grant-in-Aid for Young Scientists A and Grants-in-Aid for Scientific Research B and C from JSPS, and research grants from Japan Research Foundation for Clinical Pharmacology , Naito Foundation , Takeda Science Foundation , Uehara Memorial Foundation , and Daiichi Sankyo Scholarship Donation Program within the past three years. S.N. has also received research support, manuscript fees or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years.
Funding Information:
S.H. has received a Taikichiro Mori Memorial Research Grants, and Research Encouragement Scholarship for Graduate Students of Keio University , the Graduate School of Media and Governance Research Fund , and Keio SFC academic society grants. S.H also received JSPS Research Fellowship for Young Scientists (DC1).
Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/2
Y1 - 2023/2
N2 - Accumulating evidence indicates that pathophysiology of schizophrenia involves abnormalities in the dopamine and glutamatergic neuronal systems. Antipsychotic medications are currently used to normalize dopaminergic function for schizophrenia. However, approximately 30 % of the patients have no response to antipsychotic medications, which is classified as treatment-resistant schizophrenia (TRS). Furthermore, dopamine and glutamate levels in the neural basis have been reported to differ between TRS and non-TRS. In this study, we assumed that these differences may affect music rhythm perception and production abilities between the two groups. We examined fifty-seven schizophrenia (26 TRS, 31 non-TRS) and thirty-one healthy controls (HCs) by using the Harvard Beat Assessment Test (H-BAT). As a result, we found that rhythm production was worse in patients with TRS compared to patients with non-TRS and HCs, while no difference was observed between patients with non-TRS and HCs. In addition, rhythm perception and production abilities were impaired in the whole patient group compared with HCs. Furthermore, in the patient group, the deficits were correlated with cognitive impairments. Collectively, these results suggest that patients with schizophrenia may have rhythm processing deficits, with particular a rhythm production problem in the TRS group.
AB - Accumulating evidence indicates that pathophysiology of schizophrenia involves abnormalities in the dopamine and glutamatergic neuronal systems. Antipsychotic medications are currently used to normalize dopaminergic function for schizophrenia. However, approximately 30 % of the patients have no response to antipsychotic medications, which is classified as treatment-resistant schizophrenia (TRS). Furthermore, dopamine and glutamate levels in the neural basis have been reported to differ between TRS and non-TRS. In this study, we assumed that these differences may affect music rhythm perception and production abilities between the two groups. We examined fifty-seven schizophrenia (26 TRS, 31 non-TRS) and thirty-one healthy controls (HCs) by using the Harvard Beat Assessment Test (H-BAT). As a result, we found that rhythm production was worse in patients with TRS compared to patients with non-TRS and HCs, while no difference was observed between patients with non-TRS and HCs. In addition, rhythm perception and production abilities were impaired in the whole patient group compared with HCs. Furthermore, in the patient group, the deficits were correlated with cognitive impairments. Collectively, these results suggest that patients with schizophrenia may have rhythm processing deficits, with particular a rhythm production problem in the TRS group.
KW - H-BAT
KW - Music rhythm perception
KW - Music rhythm production
KW - Schizophrenia
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=85146329254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146329254&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2022.12.040
DO - 10.1016/j.schres.2022.12.040
M3 - Article
C2 - 36634450
AN - SCOPUS:85146329254
SN - 0920-9964
VL - 252
SP - 69
EP - 76
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -